SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma.

Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that, despite advances in treatment, remains incurable. Clinical courses can range from indolent to aggressive. As understanding of the pathophysiology improves and more targeted therapies shift to the frontline setting, treatment of relapsed and refractory MCL is becoming less defined. This review discusses the evidence of current and emerging treatment strategies for patients with relapsed and refractory MCL, including Bruton tyrosine kinase inhibitor (BTKi) therapies and immunotherapies such as bispecific T-cell engagers and chimeric antigen receptor T-cells.